Valid until: 09-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimal-sequencing-of-adcs-in-endocrine-refractory-hrher2-metastatic-breast-cancer/18104/
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
=Popular Podcasts
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Nikki Glaser Podcast
Every week comedian and infamous roaster Nikki Glaser provides a fun, fast-paced, and brutally honest look into current pop-culture and her own personal life.